ADARx Pharmaceuticals, Inc. — Form SCHEDULE 13D
Filed October 2, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
OrbiMed Advisors LLC and affiliated entities (OrbiMed Capital GP VII LLC, OrbiMed Advisors Israel II Limited, OrbiMed Israel GP II L.P., and OrbiMed Genesis GP LLC) executed a joint filing agreement dated October 2, 2026, regarding a Schedule 13D for ADARx Pharmaceuticals, Inc. common stock. The filing itself does not disclose the stake size, percentage ownership, share count, acquisition price, or any material terms—only the procedural joint filing agreement is provided here.
Why this rating
Schedule 13D filing indicates >5% stake acquisition, but core disclosure document absent; no stake size, price, or deal terms visible; routine institutional investor disclosure mechanics without quantified business impact.
See more from October 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.